UroGen Pharma Ltd. Ordinary Shares (URGN)
Stock · NASDAQ · Health Care
$43.61as of 8/28/2026
Price chart
Open in TradingViewActive signals
About URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a su…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 300
- Website
- www.urogen.com/
Fundamentals
- 1-day range
- $43.39$45.54
- Market cap
- $2.22B
- P/E (trailing)
- —
- P/E (forward)
- 15.61
- EPS (trailing)
- $-1.98
- Dividend yield
- —
- Beta
- 1.53
- Avg. volume
- 817.9K
How UroGen Pharma Ltd. Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
UroGen Pharma Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- URGNUroGen Pharma Ltd. Ordinary Shares$43.61▼ 4.15%Market cap $2.22BP/E —$15.86$50.81
- MLYSMineralys Therapeutics Inc. Common Stock$25.59▼ 1.61%Market cap $2.23BP/E —$14.94$47.65
- SLSSELLAS Life Sciences Group Inc. Common Stock$13.17▼ 13.45%Market cap $2.18BP/E —
- BHVNBiohaven Ltd. Common Shares$15.42▼ 4.37%Market cap $2.17BP/E —$7.48$18.57
- VERAVera Therapeutics Inc. Class A Common Stock$34.19▼ 1.18%Market cap $2.30BP/E —$21.2$56.05
- NUVBNuvation Bio Inc. Class A Common Stock$6.67▼ 4.65%Market cap $2.13BP/E —$2.87$9.75
- VRDNViridian Therapeutics Inc. Common Stock$23.09▼ 3.31%Market cap $2.32BP/E —$13.18$34.29
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $43.61 | ▼ 4.15% | $15.86$50.81 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $25.59 | ▼ 1.61% | $14.94$47.65 |
| SLS SELLAS Life Sciences Group Inc. Common Stock | $2.18B | — | $13.17 | ▼ 13.45% | |
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $15.42 | ▼ 4.37% | $7.48$18.57 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.30B | — | $34.19 | ▼ 1.18% | $21.2$56.05 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $6.67 | ▼ 4.65% | $2.87$9.75 |
| VRDN Viridian Therapeutics Inc. Common Stock | $2.32B | — | $23.09 | ▼ 3.31% | $13.18$34.29 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.